Variables | PEG-IFN alfa-2a | PEG-IFN alfa-2b | P* |
---|---|---|---|
(n=402, 60.8%) | (n=259, 39.2%) | ||
Genotype 1 (n=416), n (%) | 254 (61.1) | 162 (38.9) | |
Age, years† | 49 ± 11 | 51 ± 11 | 0.26 |
>50 years, n (%) | 121 (47.6) | 83 (51.2) | 0.48 |
Gender (male), n (%) | 154 (60.6) | 100 (61.7) | 0.74 |
Weight (Kg) | 67 ± 12 | 66 ± 11 | 0.93 |
≥ 75 kg, n (%) | 48 (18.9) | 34 (21.0) | 0.62 |
BMI (Kg/m2) † | 24.3 ± 3.2 | 24.4 ± 3.1 | 0.81 |
WBC (/mm3) † | 5.5 ± 2.1 | 5.2 ± 1.6 | 0.11 |
Hemoglobin (g/dL) † | 13.9 ± 1.8 | 13.9 ± 1.7 | 0.72 |
Platelet (x103/mm3) † | 173 ± 72 | 167 ± 71 | 0.46 |
ALT (IU/L) † | 104 ± 86 | 94 ± 80 | 0.26 |
HCV RNA (IU/mL) † | 2.9×106 ± 1.1×106 | 4.8×106 ± 1.9×106 | 0.24 |
Fibrosis (stage), F0-2/F3-4, n (%)§ | 62/43 (59.0/41.0) | 18/6 (75.0/25.0) | 0.17 |
Adherence, ≥ 80%/<80% | 171/83 (67.3/32.7) | 115/47(71.0/29.0) | 0.45 |
Genotype 2 or 3 (n=235), n (%) | 141 (60.0) | 94 (40.0) | |
Age, years† | 49 ± 12 | 51 ± 11 | 0.19 |
>50 years, n (%) | 61 (43.3) | 49 (52.1) | 0.19 |
Gender (male), n (%) | 79 (56.0) | 54 (57.4) | 0.89 |
Weight (Kg) | 65 ± 11 | 64 ± 10 | 0.51 |
≥ 75 kg, n (%) | 25 (17.7) | 11 (11.7) | 0.27 |
BMI (Kg/m2) † | 23.8 ± 3.3 | 23.9 ± 2.7 | 0.98 |
WBC (/mm3) † | 5.3 ± 1.5 | 5.1 ± 1.8 | 0.46 |
Hemoglobin (g/dL) † | 14.2 ± 1.6 | 13.7 ± 1.5 | 0.06 |
Platelet (x103/mm3) † | 177 ± 62 | 168 ± 65 | 0.32 |
ALT (IU/L) † | 98 ± 88 | 90 ± 89 | 0.51 |
HCV RNA (IU/mL) † | 2.0×106 ± 1.9×106 | 1.9×106 ± 1.0×106 | 0.83 |
Fibrosis (stage), F0-2/F3-4, n (%)# | 51/10 (83.6/16.4) | 8/5 (61.5/38.5) | 0.12 |
Adherence, ≥ 80%/<80% | 107/34 (75.9/24.1) | 78/16 (83.0/17.0) | 0.26 |
Genotype others (n=10), n (%) | 7(70.0) | 3 (30.0) |